MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-102202-PIP01-25-M01

Scope of the Application

Active Substance(s)

ONASEMNOGENE ABEPARVOVEC

Condition(s)

Treatment of spinal muscular atrophy.

Pharmaceutical Form(s)

Solution for injection/infusion

Route(s) of Administration

INTRAVENOUS USE; INTRATHECAL USE

Name / Corporate name of the PIP applicant

Novartis Pharmaceuticals UK Ltd.

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Novartis Pharmaceuticals UK Ltd. submitted to the licensing authority on 03/11/2025 14:19 GMT an application for a Modification

The procedure started on 28/11/2025 14:13 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-102202-PIP01-25-M01

Of 01/12/2025 12:56 GMT

On the adopted decision for ONASEMNOGENE ABEPARVOVEC (MHRA-102202-PIP01-25-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Modification for ONASEMNOGENE ABEPARVOVEC, Solution for injection/infusion , INTRAVENOUS USE; INTRATHECAL USE .

This decision is addressed to Novartis Pharmaceuticals UK Ltd., The WestWorks, 195 Wood Lane, London, UNITED KINGDOM, W12 7FQ

ANNEX I

1. Waiver

1.1 Condition:

Not applicable.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of spinal muscular atrophy.

2.2 Indication(s) targeted by the PIP:

Treatment of spinal muscular atrophy.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Solution for injection/infusion

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	7	Study 1 (AVXS-101-CL-101) Open-label, dose-escalation study to assess the efficacy, safety and tolerability of a single dose of onasemnogene abeparvovec (AVXS-101) administered intravenously in children equal or less than 6 months of age at the time of the dosing with proven mutation of the SMN1 gene. Study 2 (AVXS-101-CL-102) Open-label, dose-comparison, historical controlled study to assess the efficacy, safety and tolerability of a single dose of AVXS-101 administered intrathecally in children equal or older than 6 months and up to 60 months (1800 days) of age at the time of the dosing with a genetic diagnosis consistent with SMA, bi-allelic deletion of SMN1 and 3 copies of SMN2 without the genetic modifier who demonstrate the ability to sit unassisted for 10 or more seconds but cannot stand or walk at the time of study entry. Study 3 (AVXS-101-CL-302) Open-label, historical controlled study to assess the efficacy, safety, and tolerability of a single dose of AVXS-101 administered intravenously in children younger than 6 months of age (180 days) at the time of dosing with Spinal Muscular Atrophy

		Type 1 with One or Two SMN2 Copies. Study 4 (AVXS-101-CL-303) Open-label, historical controlled study to assess the efficacy, safety, and tolerability of a single dose of AVXS-101 administered intravenously in children younger of 6 months of age (180 days) with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies. Study 5 (AVXS-101-CL-304) Study 6, deleted during procedure MHRA-102202-PIP01-25-M01. Study 8 (OAV101B12301) Study 9 (OAV101B12302)
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	1	Measure 7 (AVXS-101-RG-001) Disease Registry: A registry should be set up to enrol patients treated with at least AVXS-101 from centres worldwide for a long-term follow-up study examining the lasting safety and efficacy of AVXS-101 for at least 15 years.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/12/2025
Deferral of one or more studies contained in the paediatric investigation plan:	Yes